Inozyme Pharma Inc's Customers Performance

Name: Inozyme Pharma Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

INZY

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


INZY's Source of Revenues		• List of INZY Customers

for the same period Inozyme Pharma Inc

• List of INZY Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Inozyme Pharma Inc's Comment on Sales, Marketing and Customers

News about Inozyme Pharma Inc Contracts

Innovative Therapeutic Advances for ENPP1 and ABCC6 Deficiencies Key Data from Inozyme Pharmas Ongoing Clinical Trials

: Inozyme Pharma, a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases involving pathological mineralization, recently made significant strides in its clinical trials for INZ-701, targeting conditions associated with ENPP1 and ABCC6 deficiencies. This article reviews the interim data presented for INZ-701 and the implications of Fast Track designation granted by the FDA, highlighting its potential to address severe unmet medical needs in affected pediatric populations.Inozyme Pharma has taken an active role in addressing the unmet therapeutic requirements for patients suffering from rare genetic disorders characterized by mineralization abnormalities, specifical...

Boston, MA In a significant stride towards addressing a critical medical need, Inozyme Pharma announced ...

Inozyme Pharma Advances in Therapeutic Innovation: FDA Grants Fast Track Designation for INZ-701 in ABCC6 Deficiency Boston, MA In a significant stride towards addressing a critical medical need, Inozyme Pharma announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for INZ-701, an investigational enzyme replacement therapy being developed for the treatment of ABCC6 Deficiency. This rare genetic disease manifests primarily in children, leading to significant calcification in blood vessels and soft tissues, with severe implications for health and quality of life.ABCC6 Deficiency is an orphan disease characterized by mutations in the ABCC6 gene, resulting in impair...

INZY's Stock Performance relative to it's Customers

INZY's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Inozyme Pharma Inc	257.11	0.00	-106.72	67
SUBTOTAL	0.00	0.00	0.00	-

Sources: Inozyme Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Inozyme Pharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Inozyme Pharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.